Viking Therapeutics continued producing eye-catching obesity data with its dual GLP-1/GIP agonist VK2735 at the ObesityWeek 2024 meeting in San Antonio, with its oral formulation showing class-leading weight loss results in updated findings from a Phase I multiple-ascending-dose (MAD) study. Meanwhile, CinFina Pharma reported weight reduction and tolerability for a pair of Phase I obesity candidates with next-generation mechanisms of action.
Key Takeaways
- The oral formulation of Viking’s VK2735, a dual GLP-1/GIP agonist, continued to show class-leading weight reduction capabilities in Phase I data reported at ObesityWeek 2024.
- Oral VK2735 dosed at 100mg daily yielded a 6.8% placebo-adjusted weight loss at 28 days, which analysts called better than four-week data for Roche’s oral GLP-1 agonist
Already drawing attention as a new entrant to the obesity drug race led by Novo Nordisk and Lilly via Phase II success with subcutaneous VK2735, Viking shook up the competition even further in March by reporting 5.3% weight reduction at four weeks with an oral 40mg daily dose of the same molecule
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
